Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on Research in Marfan Syndrome and Related Disorders

This publication has 73 references indexed in Scilit:

• Angiotensin II Blockade and Aortic-Root Dilation in Marfan's Syndrome
  New England Journal of Medicine, 2008
• Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
  American Heart Journal, 2007
• Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states
  Nature Medicine, 2007
• Clinical features in a family with an R460H mutation in transforming growth factor β receptor 2 gene
  Journal of Medical Genetics, 2006
• Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
  Science, 2006
• Mutations in NOTCH1 cause aortic valve disease
  Nature, 2005
• Usefulness of Enalapril Versus Propranolol or Atenolol for Prevention of Aortic Dilation in Patients With the Marfan Syndrome
  The American Journal of Cardiology, 2005
• Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome
  American Heart Journal, 1999
• Aortic biomechanical properties in pediatric patients with the marfan syndrome, and the effects of atenolol
  The American Journal of Cardiology, 1993
• Aortic aneurysm in patients with functionally normal or minimally stenotic bicuspid aortic valve
  The American Journal of Cardiology, 1991